How to Build Better Bridge and Fast-Start Patient Assistance Programs

CHAPEL HILL, N.C., Feb. 08, 2021/PRNewswire/ -- Patient assistance programs have become important ways for pharma to help patients navigate expensive therapies or gain access to new products that are pending coverage by payers.

Fast start programs are typically patient assistance provided for new drugs with pending coverage approval; bridge programs are patient assistance provided by drug makers to reduce or eliminate costs for eligible individuals.

Best Practices, LLC prepared this research to identify and spotlight current trends and future directions of bridge assistance and fast start programs. The study found respondents thought that bridge Programs are among the most highly-rated patient assistance programs and support services. The study probes the prevalence and impact of such bridge programs and examines their role during new product introduction. The research also evaluates bridge programs' role in the context of overall pull through services to help patients get quickly and effectively started on new medicines.

"Benchmarking Meta-Analysis of New-Product Bridge and Fast-Start Patient Assistance Programs" research goals:

Identify and spotlight current trends and future directions of bridge assistance programs supporting new biopharmaceutical product programs Probe the prevalence and impact of such bridge programs Examine their role during new product introduction Evaluate bridge programs role in the context of overall pull through services to help patients get quickly and effectively started on new medicines This analysis is informed by nine benchmarking field studies probing patient assistance programs.

To learn more about this report, download a complimentary report excerpt at https://www.best-in-class.com/rw92.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.